Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Merck And Wellcome Launch Vaccine Venture
by Michael McCoy
September 21, 2009
| A version of this story appeared in
Volume 87, Issue 38
Merck & Co. and the Wellcome Trust have created a research and development joint venture focused on affordable vaccines for poor countries. The partners will invest about $130 million over the next seven years to support a staff of 60 researchers. They say the venture marks the first time a drug company and a research charity have formed such an equally funded and separate entity. It will be based in India and called MSD Wellcome Trust Hilleman Laboratories, after pioneering vaccine scientist Maurice R. Hilleman.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter